Zhan Yujia, Yue Honghua, Liang Weitao, Wu Zhong
Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu 610017, China.
J Cardiovasc Dev Dis. 2022 Sep 2;9(9):292. doi: 10.3390/jcdd9090292.
The World Health Organization announced that COVID-19, with SARS-CoV-2 as its pathogen, had become a pandemic on 11 March 2020. Today, the global epidemic situation is still serious. With the development of research, cardiovascular injury in patients with COVID-19, such as arrhythmia, myocardial injury, and heart failure, is the second major symptom in addition to respiratory symptoms, and cardiovascular injury is related to the prognosis and mortality of patients. The incidence of arrhythmia in COVID-19 patients ranges from 10% to 20%. The potential mechanisms include viral infection-induced angiotensin-converting enzyme 2 expression change, myocarditis, cytokine storm, cardiac injury, electrophysiological effects, hypoxemia, myocardial strain, electrolyte abnormalities, intravascular volume imbalance, drug toxicities and interactions, and stress response caused by virus infection. COVID-19 complicated with arrhythmia needs to be accounted for and integrated in management. This article reviews the incidence, potential mechanisms, and related management measures of arrhythmia in COVID-19 patients.
世界卫生组织宣布,以严重急性呼吸综合征冠状病毒2(SARS-CoV-2)为病原体的2019冠状病毒病(COVID-19)于2020年3月11日成为大流行病。如今,全球疫情形势依然严峻。随着研究的开展,COVID-19患者的心血管损伤,如心律失常、心肌损伤和心力衰竭,是除呼吸道症状外的第二大主要症状,且心血管损伤与患者的预后和死亡率相关。COVID-19患者心律失常的发生率在10%至20%之间。潜在机制包括病毒感染引起的血管紧张素转换酶2表达变化、心肌炎、细胞因子风暴、心脏损伤、电生理效应、低氧血症、心肌应变、电解质异常、血管内容量失衡、药物毒性及相互作用,以及病毒感染引起的应激反应。COVID-19合并心律失常在管理中需要加以考虑和综合处理。本文综述了COVID-19患者心律失常的发生率、潜在机制及相关管理措施。